Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of clocortolone pivalate (a topical corticosteroid) and palmitoylethanolamide (PEA, a nonsteroidal anti-inflammatory compound) is used for treating inflammatory skin conditions, particularly atopic dermatitis. **Clocortolone pivalate** is a moderate potency topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses. **Palmitoylethanolamide (PEA)** is an endogenous fatty acid that is often deficient in patients with atopic dermatitis. It possesses anti-inflammatory and neuroprotective effects. PEA has been shown to reduce pain and inflammation in various conditions. This combination is designed to leverage the anti-inflammatory properties of both compounds, with the PEA component potentially allowing for reduced use of the corticosteroid while maintaining efficacy. It is applied topically, typically twice daily.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clocortolone Pivalate and Palmitoylethanolamide (PEA) Topical Combination.